BioInvent International has entered into a license and discovery agreement with Daiichi Sankyo Co. for the development of therapeutic antibodies against multiple targets. Daiichi Sankyo will have access to BioInvent’s discovery and development technology platform, n-CoDeR library, and in-house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries. BioInvent will receive an upfront access fee and annual mai...